182 related articles for article (PubMed ID: 16891862)
1. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
2. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
[TBL] [Abstract][Full Text] [Related]
4. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
6. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
8. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Balducci L; Mo M; Abella E; Saven A
Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
11. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
[TBL] [Abstract][Full Text] [Related]
12. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy.
McBride A; Alrawashdh N; Bartels T; Moore L; Persky D; Abraham I
Future Oncol; 2021 Sep; 17(26):3485-3497. PubMed ID: 34241542
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
Hernàndez DE; Hernàndez AE
Eur J Cancer Care (Engl); 2006 Dec; 15(5):493-6. PubMed ID: 17177909
[TBL] [Abstract][Full Text] [Related]
16. P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
Cocconi G; Franciosi V; Dodero A; Bologna A; Vasini G; De Lisi V; Di Blasio B; Ceci G; Camisa R; Cascinu S
Am J Clin Oncol; 2003 Dec; 26(6):535-42. PubMed ID: 14663368
[TBL] [Abstract][Full Text] [Related]
17. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.
Dann EJ; Epelbaum R; Avivi I; Ben Shahar M; Haim N; Rowe JM; Blumenfeld Z
Hum Reprod; 2005 Aug; 20(8):2247-9. PubMed ID: 15817583
[TBL] [Abstract][Full Text] [Related]
18. R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.
Rueda A; Sabin P; Rifá J; Llanos M; Gómez-Codina J; Lobo F; García R; Herrero J; Provencio M; Jara C;
Hematol Oncol; 2008 Mar; 26(1):27-32. PubMed ID: 17868190
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Korolenko VO; Gershanovich ML; Leenman EE; Tikhonova VV
Vopr Onkol; 2003; 49(4):459-63. PubMed ID: 14569937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
